CoChat

Non-Persistence and Non-Adherence of Patients with Type 2 Diabetes Mellitus in Therapy with GLP-1 Receptor Agonists: A Retrospective Analysis

Open access
Wilke, Thomas, Mueller, Sabrina, Groth, Antje, Berg, Bjoern, Fuchs, Andreas, Sikirica, Mirko, Logie, John, Martin, Alan, Maywald, Ulf · 2016 · Diabetes Therapy

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Our main aim was to assess the level of persistence and adherence to therapy with glucagon-like peptide-1 (GLP-1) receptor agonists in type 2 diabetes mellitus (T2DM) patients in the United Kingdom (UK) and Germany, also by comparing once- (OD) with twice-a-day (BID) therapy. METHODS: We used two large retrospective datasets: a German claims dataset and the UK General Practitioner (GP)-based Clinical Practice Research Datalink (CPRD) dataset (2010-2012). All continuously insured T2DM patients with at least one outpatient/inpatient T2DM diagnosis were observed starting with the first prescription of a GLP-1 receptor agonist. Non-persistence (NP) was defined as treatment gap >90 days. Non-adherence (NA) was defined as medication possession ratio <80%, calculated during a period in which a patient continued therapy (no treatment gap >90 days) only. RESULTS: In the UK sample, 1905 T2DM patients started a treatment with GLP-1 receptor agonists (mean age: 55.5 years, 47.2% female). In the German sample, 1627 T2DM patients started a treatment with GLP-1 receptor agonists (mean age: 56.6 years, 51.4% female). Percentage of NP patients after 12 months was 29.5% in the UK and 36.4% in the German sample. In both countries, a BID treatment was associated with a higher probability to discontinue a treatment with GLP-1 receptor agonists earlier than an OD treatment (hazard ratio [HR] = 1.431 in UK and HR = 1.314 in Germany). The percentages of patients considered NA were 20.2%/20.0%/20.5% (all/OD/BID) for the UK sample, and 19.9%/19.2%/21.8% (all/OD/BID) for the German sample. CONCLUSION: NP and NA to treatment with GLP-1 receptor agonists in both UK and Germany appear to be similar. Persistence to OD treatment is higher than to BID treatment in both the UK and Germany.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13300-015-0149-4

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Methodology of analysis. The figure shows how reference period, index date and observational period have been defined. GLP-1 glucagon-like peptide-1, MPR medication possession ratio
Fig. 1 Methodology of analysis. The figure shows how reference period, index date and observational period have been defined. GLP-1 glucagon-like peptide-1, MPR medication possession ratioCC BY-NC · PubMed Central
Fig. 2 Kaplan–Meier curves for percentage of T2DM patients persistent to their therapy with GLP-1 receptor agonists. The figure describes percentage of T2DM still persistent (no gap >90 days) to their therapy with GLP-1 receptor agonists over time (12 months) with regards to UK-T2DM and GER-T2DM patients having started a therapy with GLP-1 receptor agonists. T2DM type 2 diabetes mellitus, GLP-1 glucagon-like peptide-1, UK United Kingdom, GER Germany
Fig. 2 Kaplan–Meier curves for percentage of T2DM patients persistent to their therapy with GLP-1 receptor agonists. The figure describes percentage of T2DM still persistent (no gap >90 days) to their therapy with GLP-1 receptor agonists over time (12 months) with regards to UK-T2DM and GER-T2DM patients having started a therapy with GLP-1 receptor agonists. T2DM type 2 diabetes mellitus, GLP-1 glucagon-like peptide-1, UK United Kingdom, GER GermanyCC BY-NC · PubMed Central
Fig. 3 Kaplan–Meier curves for percentage of persistent GLP-1 patients during 12 months after therapy initiation. The figure describes percentage of T2DM patients having started a therapy with GLP-1 receptor agonists (four groups: UK- and GER-T2DM patients having started either an OD/BID therapy with GLP-1 receptor agonists) being still persistent (no gap >90 days) with therapy over time (12 months). Patients having switched their therapy with GLP-1 receptor agonists between OD and BID were excluded. GLP-1 glucagon-like peptide-1, T2DM type 2 diabetes mellitus, UK United Kingdom, GER Germany, OD once daily, BID twice daily
Fig. 3 Kaplan–Meier curves for percentage of persistent GLP-1 patients during 12 months after therapy initiation. The figure describes percentage of T2DM patients having started a therapy with GLP-1 receptor agonists (four groups: UK- and GER-T2DM patients having started either an OD/BID therapy with GLP-1 receptor agonists) being still persistent (no gap >90 days) with therapy over time (12 months). Patients having switched their therapy with GLP-1 receptor agonists between OD and BID were excluded. GLP-1 glucagon-like peptide-1, T2DM type 2 diabetes mellitus, UK United Kingdom, GER Germany, OD once daily, BID twice dailyCC BY-NC · PubMed Central
Fig. 4 Factors associated with early GLP-1 discontinuation. The figure shows the results of the multivariable Cox regression analyses with regards to independent factors influencing early GLP-1 discontinuation (4a GER, 4b UK). GLP-1 glucagon-like peptide-1, UK United Kingdom, GER Germany, CI confidence interval, CCI Charlson Comorbidity Index, BID twice daily
Fig. 4 Factors associated with early GLP-1 discontinuation. The figure shows the results of the multivariable Cox regression analyses with regards to independent factors influencing early GLP-1 discontinuation (4a GER, 4b UK). GLP-1 glucagon-like peptide-1, UK United Kingdom, GER Germany, CI confidence interval, CCI Charlson Comorbidity Index, BID twice dailyCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Research works printed but not linked: 1

  1. Ostenson CG, Matthaei S, Reaney M, et al. Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries. Diabetes Metab Syndr Obes. 2014;6:171–85.

Cited by

See all 46

Metadata

Authors
Wilke, T., Mueller, S., Groth, A., Berg, B., Fuchs, A., Sikirica, M., Logie, J., Martin, A., & Maywald, U.
Affiliations
  • Wismar University of Applied Sciences (DE)
  • GlaxoSmithKline (United States) (US)
  • GlaxoSmithKline (United Kingdom) (GB)
Corresponding author
Wilke, Thomas
Venue
Diabetes Therapy
Published
2015-12-22
Volume
7
Issue
1
Pages
105-124
ISSN
  • 1869-6953 (ISSN-L)
  • 1869-6961
OpenAlex
W2211791999
Cited by
41
References
27
Citations by year
2026: 2 · 2025: 3 · 2024: 1 · 2022: 4 · 2021: 10 · 2020: 4 · 2019: 3 · 2018: 6 · 2017: 4 · 2016: 4
FWCI
5.45
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc
  • creativecommons.org/licenses/by/4.0 (tdm)
Locations
  • Diabetes Therapy (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
GlaxoSmithKline
Topics
  • Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
Keywords
type 2 diabetes, GLP-1 receptor agonists, treatment persistence, medication adherence, once-daily dosing, twice-daily dosing, treatment discontinuation, medication possession ratio, treatment gap

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Non-Persistence and Non-Adherence of Patients with Type 2 Diabetes Mellitus in Therapy with GLP-1 Receptor Agonists: A Retrospective Analysis. https://app.cochat.ai/papers/10.1007/s13300-015-0149-4
The paper
Wilke, T., Mueller, S., Groth, A., Berg, B., Fuchs, A., Sikirica, M., Logie, J., Martin, A., & Maywald, U. (2016). Non-Persistence and Non-Adherence of Patients with Type 2 Diabetes Mellitus in Therapy with GLP-1 Receptor Agonists: A Retrospective Analysis. Diabetes Therapy. https://doi.org/10.1007/s13300-015-0149-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.